Is SMG a Buy or a Sell? The Bull and Bear Case (2026)
Last updated October 2026
Short answer
Both cases are real, which is why the question is contested. The bull case for The Scotts Miracle-Gro Company (SMG) rests on Refocus after the Hawthorne exit: Selling Hawthorne to Vireo Growth removes a business that swung wildly with the cannabis-cultivation cycle and had weighed on margins and write-downs for years. The bear case rests on the biggest risk is seasonality and weather: the bulk of sales occur in spring, so a cold, wet, or drought-stricken season can hurt a full fiscal year with little chance to recover. Analysts covering it publish targets from $60.00 to $82.00 against a $54.57 price, so even the professionals disagree by 30% of their own average. We do not give a verdict. What follows is each case at full strength, so you can decide which set of assumptions you actually believe. Walnut is not an investment adviser.
The Scotts Miracle-Gro Company is the dominant branded marketer of consumer lawn and garden products in North America, with roughly $3.3-3.5 billion in annual sales and a portfolio of household names including Scotts, Miracle-Gro, Ortho, Tomcat, and the consumer Roundup brand it markets under license. Its products span grass seed, fertilizers, soils, growing media, controls, and pest and weed treatments sold largely through big-box retailers such as Home Depot, Lowe's, and Walmart. Because most of the business happens in a compressed spring and early-summer window, Scotts is intensely seasonal and weather-dependent: a cold, wet spring can dent a whole year, while good weather and an engaged do-it-yourself consumer lift the entire category. The defining recent event is the April 9, 2026 sale of The Hawthorne Gardening Company, its indoor, hydroponic, and cannabis-cultivation supplies business, to Vireo Growth in exchange for Vireo equity and warrants rather than cash. That exit ends a multi-year drag from the collapse of the cannabis-cultivation boom and refocuses Scotts on its core U.S. lawn and garden franchise. The 2026 spring season delivered: fiscal second-quarter sales were about $1.46 billion with EPS of $4.53 (versus a $4.01 estimate), and the fiscal third quarter, ended June 27, 2026, brought sales of about $1.17 billion, net income of about $112 million, and EPS of $2.82 against a $2.52 consensus. In September the company redeemed all $250 million of its 5.25% notes due 2026, renewed its $750 million receivables facility to August 2027, began its $500 million buyback with $25 million of repurchases in August, said it had reached its $275 million free cash flow target, and reaffirmed fiscal 2026 non-GAAP EPS guidance of $4.30-4.45. It also announced a Black Kow acquisition to expand its soil-amendment line, and pairs all of this with an SMG 2.0 plan targeting about $1 billion of incremental sales by 2030 under president and CEO Nate Baxter. Even so, the stock closed near $55.52 on October 16, 2026, down about 7% year to date and 19% over three months, before a UBS upgrade to Buy on October 15. Full-year results are due November 4, 2026, when the seasonally weak fiscal fourth quarter is expected to show a loss (consensus about -$2.21 per share). The investment picture combines brand strength and improving cash flow against roughly $2.5 billion of debt, retailer concentration, and weather risk.
The bull case: what would have to be true for $82.00
The most optimistic published target on SMG is $82.00, +50.3% from the $54.57 price as of October 2026. Getting there needs the following to work close to its best case, not merely to avoid going wrong.
1. Refocus after the Hawthorne exit
Selling Hawthorne to Vireo Growth removes a business that swung wildly with the cannabis-cultivation cycle and had weighed on margins and write-downs for years. The company now concentrates capital and management attention on its core, higher-return U.S. lawn and garden brands. The trade-off is that Scotts took Vireo equity rather than cash, so realized value depends on how that stake performs over time.
2. Brand moat and retail distribution
Scotts, Miracle-Gro, and Ortho are category-leading brands with shelf space and retailer relationships that are hard for smaller rivals to replicate. That scale supports pricing power and marketing reach in a fragmented lawn and garden market. The flip side is heavy dependence on a handful of big-box customers, so shelf decisions, private-label pressure, or a weak retail season can move results quickly.
3. SMG 2.0 growth and cash-return plan
Management's SMG 2.0 program targets roughly $1 billion of incremental sales by 2030 through innovation, marketing, and category expansion, alongside a share-repurchase authorization of about $500 million and free-cash-flow generation used to pay down debt. Progress became concrete in September 2026: Scotts redeemed $250 million of 2026 notes, said it had hit its $275 million free cash flow target for fiscal 2026, expected leverage to fall into the high 3s, and made its first $25 million of buybacks. A Black Kow soil-amendment acquisition and a new CIO appointment in October point to the growth and technology side of the plan. Delivering on both growth and deleveraging at once is the crux of the bull case.
4. Seasonal cash flow and dividend
Scotts throws off most of its cash in a concentrated spring window and pays a meaningful quarterly dividend of $0.66 per share, or $2.64 a year, which works out to a yield near 4.9% at the October 2026 share price. That seasonal, cash-generative profile can support capital returns and debt reduction in good years. But the dividend currently exceeds trailing GAAP earnings (a payout ratio around 100%), and because sell-through is compressed into a few months, a poor spring or a pullback in consumer spending can pressure both cash flow and the flexibility to fund the dividend and buyback comfortably.
The bear case: what would have to be true for $60.00
The most pessimistic published target is $60.00, +10.0% from the current price. That is not a floor and not a forecast; it is roughly what one analyst thinks The Scotts Miracle-Gro Company is worth if the risks below bite instead of the drivers above.
The biggest risk is seasonality and weather: the bulk of sales occur in spring, so a cold, wet, or drought-stricken season can hurt a full fiscal year with little chance to recover. Retailer concentration is a structural risk because a large share of revenue flows through a few big-box chains, leaving Scotts exposed to their inventory decisions, shelf choices, and private-label competition. The historical debt load, built up partly during the Hawthorne expansion, still stands near $2.5 billion against under $30 million of cash, and leverage is only expected to fall to the high 3s after fiscal 2026; and rising input or commodity costs can squeeze margins. Consumer discretionary spending on lawn and garden projects softens in downturns. Finally, the Hawthorne sale was paid in Vireo equity rather than cash, so the ultimate value Scotts realizes depends on a volatile, small-cap cannabis stock outside its control.
The bear case deserves the same attention as the bull case, and usually gets less. If you are holding SMG already, the question is not whether these risks exist but whether any of them has moved from possible to actually happening in the reported numbers.
Where analysts land on SMG
6 analysts cover SMG, with an average target of $72.83 (+33.5% against $54.57) and a split of 6 buy, 2 hold, 0 sell. Bear in mind sell-side ratings skew positive across the whole market, so that split is not a balanced vote. The full target table, the recent rating actions by firm, and how the consensus has shifted are on the SMG forecast and price target page.
How is SMG valued? (as of October 2026)
Snapshot for SMG as of October 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
- Revenue (TTM): ~$3.48B; fiscal Q3 2026 (June) sales ~$1.17B
- Net income (TTM): ~$155M; profit margin ~2% (GAAP), operating margin ~17%
- Latest quarter EPS: $2.82 vs ~$2.52 estimate (fiscal Q3 2026)
- FY2026 guidance (reaffirmed Sept 2026): Non-GAAP EPS $4.30-4.45; free cash flow ~$275M
- P/E (trailing / forward): ~19.8x / ~11.8x
- Dividend yield: ~4.9% ($2.64 a year)
- Debt / cash: ~$2.49B / ~$28M
- Market cap: ~$3.2B at ~$55.52 (Oct 16, 2026)
Scotts is intensely seasonal, so a single quarter, especially the spring one, overstates run-rate profitability, and full-year non-GAAP EPS of $4.30-4.45 is the more meaningful lens; on that basis the stock trades near 12-13 times earnings. The trailing GAAP P/E near 20 and a dividend that roughly equals GAAP earnings show how much one-off charges and the Hawthorne exit still weigh on reported results. Figures are approximate and as of October 16, 2026; full-year results arrive November 4.
How do you decide if SMG is a buy?
Rather than asking whether SMG is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the bull case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold SMG indirectly through an index or sector ETF before adding more.
What would change your mind on SMG
Write the tripwires down before you need them. Deciding what would falsify your view is far harder once a position is moving against you.
- Bull case breaks if: Refocus after the Hawthorne exit stalls in the reported numbers rather than in the narrative around them.
- Bear case breaks if: the biggest risk is seasonality and weather: the bulk of sales occur in spring, so a cold, wet, or drought-stricken season can hurt a full fiscal year with little chance to recover fails to materialise over several reporting periods while the drivers keep compounding.
- Neither matters if: the position has grown large enough that being wrong would damage the whole portfolio. Sizing overrides the argument.
For the full picture, see the SMG stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about SMG against your real portfolio and see your actual exposure before deciding.
Investing in The Scotts Miracle-Gro Company with AI
Connect the broker you already use and ask Walnut's AI how SMG fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.
FAQ
Is SMG a good stock to buy right now?
+
That depends on which case you find more convincing, and both are on this page. The bull case rests on Refocus after the Hawthorne exit, with revenue (ttm) at ~$3.48B; fiscal Q3 2026 (June) sales ~$1.17B. The bear case rests on the biggest risk is seasonality and weather: the bulk of sales occur in spring, so a cold, wet, or drought-stricken season can hurt a full fiscal year with little chance to recover. Analysts covering it are spread from $60.00 to $82.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.
Should I sell SMG?
+
Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. The biggest risk is seasonality and weather: the bulk of sales occur in spring, so a cold, wet, or drought-stricken season can hurt a full fiscal year with little chance to recover. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $60.00, +10.0% from the $54.57 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.
What is the bull case for SMG?
+
Refocus after the Hawthorne exit. Selling Hawthorne to Vireo Growth removes a business that swung wildly with the cannabis-cultivation cycle and had weighed on margins and write-downs for years. The most optimistic analyst target on SMG is $82.00, +50.3% from the $54.57 price. That figure is only reachable if this thesis works close to its best case.
What is the bear case for SMG?
+
The biggest risk is seasonality and weather: the bulk of sales occur in spring, so a cold, wet, or drought-stricken season can hurt a full fiscal year with little chance to recover. Retailer concentration is a structural risk because a large share of revenue flows through a few big-box chains, leaving Scotts exposed to their inventory decisions, shelf choices, and private-label competition. The historical debt load, built up partly during the Hawthorne expansion, still stands near $2.5 billion against under $30 million of cash, and leverage is only expected to fall to the high 3s after fiscal 2026; and rising input or commodity costs can squeeze margins. Consumer discretionary spending on lawn and garden projects softens in downturns. Finally, the Hawthorne sale was paid in Vireo equity rather than cash, so the ultimate value Scotts realizes depends on a volatile, small-cap cannabis stock outside its control. The most pessimistic published target is $60.00, +10.0% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.
What does The Scotts Miracle-Gro Company do?
+
The Scotts Miracle-Gro Company is the dominant branded marketer of consumer lawn and garden products in North America, with roughly $3.4 billion in annual sales and a portfolio of
What would have to change for SMG to stop being worth holding?
+
Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Refocus after the Hawthorne exit) stalling in the reported numbers rather than in the narrative, the risk above (the biggest risk is seasonality and weather: the bulk of sales occur in spring, so a cold, wet, or drought-stricken season can hurt a full fiscal year with little chance to recover) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.
Is SMG a good stock to buy right now?
+
That depends on your goals, time horizon, and risk tolerance, and this is not investment advice. The bull case is a refocused, brand-led lawn and garden leader after the Hawthorne exit, with a buyback, a solid dividend, and an SMG 2.0 growth plan. The bear case is heavy seasonality and weather risk, retailer concentration, a historical debt load, and the fact that the Hawthorne sale was paid in volatile Vireo equity. Weigh both against your portfolio.
What does Scotts Miracle-Gro actually do?
+
Scotts is the leading branded consumer lawn and garden company in North America. It markets grass seed, fertilizers, soils, growing media, and pest and weed controls under names like Scotts, Miracle-Gro, Ortho, and the consumer Roundup brand, sold mainly through big-box retailers. Most of its sales happen in the spring and early-summer gardening season.
Did Scotts Miracle-Gro sell its cannabis business?
+
Yes. On April 9, 2026 Scotts completed the sale of The Hawthorne Gardening Company, its indoor, hydroponic, and cannabis-cultivation supplies unit, to Vireo Growth. Scotts received Vireo equity and warrants rather than cash. The move exits a business that had struggled since the cannabis-cultivation boom faded and refocuses the company on its core lawn and garden brands.
Walnut is informational, not investment advice, and gives no verdict on SMG. Analyst targets referenced here come from a October 2026 pull of published third-party research and change constantly. Verify current figures with your broker before acting on them.